Sulfonylurea, an Update

Sulfonylureas (SUs) are widely prescribed in the treatment of type 2 diabetes. Despite availability several newer agents, SUs still play an important role glucose-lowering therapy. However, over last decade, there is a degrowth older agents (SUs and thiazolidinediones) prescriptions with emergence such as dipeptidyl peptidase-4 inhibitors, sodium glucose cotransporter-2 inhibitors glucagon-like peptide-1 receptor agonists. The modern clinical practice poses ongoing debate. With active marketing these drugs, concerns regarding hypoglycemia, secondary failure cardiovascular safety tend to be overstated, especially when considering SUs. Some evidence has suggested that (such gliclazide modified release glimepiride) have lower hypoglycemia rates decreased risk mortality from all-cause disease compared conventional patients Appropriate judgement coupled patient-centered approach crucial achieve best outcome Modern should also considered based on their safety, efficacy, low cost choosing anti-hyperglycemic agents. Keywords: Cardiovascular diseases; Diabetes mellitus; 2; insulin secretion